Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NEO1132
i
Other names:
NEO1132, NEO 1132
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Epigenetix, adMare BioInnovations
Drug class:
CBP inhibitor, BRD4 inhibitor, EP300 inhibitor
Related drugs:
‹
eribulin mesylate (47)
PRI724 (5)
CCS1477 (4)
FT-6876 (1)
AU-18069 (0)
AUR-107 (0)
E7386 (0)
EP31670 (0)
OTX015 (10)
BI2536 (3)
SRA515 (3)
GS-626510 (2)
I-BET151 (2)
PLX51107 (2)
SRX3262 (1)
ARV-825 (0)
HH3806 (0)
NHWD-870 (0)
NUV-868 (0)
OPN-2853 (0)
PH-3861 (0)
PH-894 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SRX3177 (0)
eribulin mesylate (47)
PRI724 (5)
CCS1477 (4)
FT-6876 (1)
AU-18069 (0)
AUR-107 (0)
E7386 (0)
EP31670 (0)
OTX015 (10)
BI2536 (3)
SRA515 (3)
GS-626510 (2)
I-BET151 (2)
PLX51107 (2)
SRX3262 (1)
ARV-825 (0)
HH3806 (0)
NHWD-870 (0)
NUV-868 (0)
OPN-2853 (0)
PH-3861 (0)
PH-894 (0)
SF1126 (0)
SF2523 (0)
SF2535 (0)
SRX3177 (0)
›
Associations
News
Trials
Filter by
Latest
4years
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in Multiple Myeloma. (PubMed, Eur J Haematol)
The dual inhibition of BET and CBP/EP300 has potential therapeutic benefits for patients with MM.
4 years ago
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EP300 (E1A binding protein p300) • IRF4 (Interferon regulatory factor 4)
|
JQ-1 • birabresib (OTX015) • molibresib (GSK525762) • I-BET151 • EP31670 • NEO1132
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login